What's happening
Live detector signal
Generated 00:51 ET
ALGS — Aligos Therapeutics, Inc. Common Stock is down 20.0%, at 3.16, on $289.8K traded, 2.2× 20-day volume. Score 76. Primary driver: $290K traded. Supply intelligence: clean gap · 72.
Get alerts on $ALGS
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
5.6M
2026-08-14
Shares out
6.2M
latest detail
Market cap
$16.0M
at ref price
Short interest
12.2%
2026-10-30
Float rotation
0.02×
latest snapshot
20d dollar vol
$221.1K
baseline
Gap quality
clean gap · 72
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
low float
detector reason
Supply factor
elevated short interest
detector reason
Supply factor
nano-cap supply profile
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-11-10 13:55 ETSignalAligos Therapeutics, Inc. Common Stock is down 20.0%, at 3.16, on $289.8K traded, 2.2× 20-day volume. Score 76. Primary driver: $290K traded. Supply intelligence: clean gap · 72.
2026-11-068-KItem 2.02 — Results of operations and financial condition; Item 9.01 — Financial statements and exhibits SEC
2026-08-068-KItem 2.02 — Results of operations and financial condition; Item 9.01 — Financial statements and exhibits SEC
2026-06-268-KItem 5.02 — Director or officer departure/election/appointment; Item 9.01 — Financial statements and exhibits SEC
2026-05-27 02:30 ETFDA / ClinicalAligos Therapeutics Presents Positive Data at the EASL Congress 2026 News
2026-04-16 06:00 ETContractAligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection News
2026-03-05 08:00 ETFDA / ClinicalAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results News
2026-02-23 08:00 ETFDA / ClinicalAligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) News
Latest detector signalscore 76